LUNG CANCER

Dr Joel Neal reviews data from the pivotal clinical trial leading to the FDA approval of mobocertinib for EGFR exon 20-mutated advanced or metastatic lung cancers.

Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.

Dr Piotrowska highlights the currently approved targeted therapies for EGFR exon 20 mutation-positive mNSCLC.

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed with participants which patients are candidates for chemoimmunotherapy for advanced non–small cell lung cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Benjamin Levy, MD, discussed the current targeted treatment options that target lung cancers that are positive for ALK rearrangements.

Frontline treatment with dostarlimab and chemotherapy reduced the risk of disease progression and led to better objective response rates and progression-free survival vs pembrolizumab in patients with metastatic non-squamous non–small cell lung cancer.

Nurse Practitioner Lauren Welch and Dr Michelle Shiller explain if and when they would offer repeat liquid or tissue biopsies to a patient with mNSCLC, and discuss how often patients request “serial biopsies” for detecting treatment response and/or disease progression.

A key opinion leader muses on the treatments she would consider for a patient with mNSCLC, an EGFR exon 20 mutation, and brain metastases.

Shirish M. Gadgeel, MD, MBBS, discusses the results of the KRYSTAL-1 trial trial of adagrasib in patients with KRAS-positive non–small cell lung cancer.

Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.

An interim overall survival analysis of the novel therapy sitravatinib combined with nivolumab has cleared the way for a continuation of the phase 3 SAPPHIRE study in patients with advanced non-squamous non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.

Edward B. Garon, MD, MS, provides an overview of the phase 3 CANOPY-A study.

The panel reviews the first- and second-line treatment options for the patient in the presented case, before and after knowing her molecular testing results.

Michelle Shiller, DO, AP/CP, MGP, describes the process of tissue biopsy testing at her institution from start to finish, and Zosia Piotrowska, MD, explains the likelihood of targetable alterations in cases of mNSCLC in patients with no smoking history.

Clinically meaningful differentiation across efficacy measures were seen in patients administered domvanalimb in combination with zimberleimab or etrumadenant vs zimberelimab monotherapy.

In this companion article, Dr Paul Bunn discuss the implications from the pooled results of trilaciclib on chemotherapy induced myelosuppression (CIM) and reviews management strategies for patients that might develop neutropenia while on chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).

Dr Paul Bunn briefly reviews key efficacy data from a pooled analyses of trilaciclib in chemotherapy induced myelosuppression and discusses strategies to manage neutropenia in patients receiving chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed 3-year data on overall survival and subgroup analysis for the CheckMate 9LA trial of ipilimumab, nivolumab, and 2 cycles of chemotherapy.

On the heels of a negative ODAC vote, poziotinib has was not approved by the FDA on it PDUFA date, and the developer of poziotinib will stop development immediately.

Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.

Joel Neal, MD, PhD, presents the case of a 66-year-old woman with no smoking history and a diagnosis of EGFR exon 20 mutation-positive mNSCLC.

Zosia Piotrowska, MD, explains molecular testing methods that can discover molecular alterations in common biomarkers in patients with mNSCLC.

A 5-year survival update of CheckMate 227 support the use of nivolumab plus ipilimumab in patients with advanced non–small cell lung cancer.

Surabhi Pathak, MD, reviews current and upcoming targeted treatments in patients with non–small cell lung cancer for Lung Cancer Awareness Month.